Reduced fractionation in lung RT during COVID-19
TL;DRCOVID-era consensus on shorter curative lung RT: 30Gy to 34Gy single-fraction SABR, 50Gy in 5 fractions, and 15-fraction schedules modelled against 55Gy/20.
The transferable part is the radiobiology: at α/β of 10, 52Gy/15 is quoted as isoeffective with 55Gy/20 for tumour control, and at α/β of 3, 50Gy/15 is isotoxic for late effects. That is a modelled bridge from 20 to 15 fractions, not outcome data, and OAR constraints still gate it.
In a small peripheral lung tumour clear of the chest wall, this supports single-fraction SABR as a reduced-visit option; it does not extend to lesions abutting the chest wall, where cited chest wall toxicity was 30.6%.
The usable content is the fractionation map: 30Gy to 34Gy single-fraction SABR when the tumour is clear of the chest wall, and 52Gy/15 or 50Gy/15 modelled against 55Gy/20. Chest wall proximity (30.6% vs 8.2% toxicity) is the geometry gate for single fraction.
8 details 2 trials watching
Consensus guidance from lung clinical oncologists, built from a literature search plus published and unpublished centre audits. No new patient data.
Options span 30Gy to 34Gy single-fraction SABR for small peripheral tumours, 50Gy in 5 fractions (Glasgow, RTOG 0813 constraints), 15-fraction radical schedules modelled against 55Gy/20, and 40Gy in 15 fractions with concurrent or sequential chemotherapy.
Cited single-fraction data put chest wall toxicity at 30.6% for lesions abutting the chest wall vs 8.2% for tumours ≤1cm from it. One concurrent chemoRT cohort reported 25% ≥grade 3 oesophagitis and 10% ≥grade 3 pneumonitis.
The 5-fraction SABR recommendation leans on RTOG 0813 dose constraints rather than new dose-finding. Hypofractionated radical schedules are justified by isoeffect calculation and retrospective series reporting outcomes comparable to ≥60Gy conventional RT.
Toxicity numbers come from mixed cited cohorts with different regimens and selection, so they are not directly comparable across rows. The isotoxicity claims depend on assumed α/β values.
The document reframes fractionation as a risk-benefit trade under infection risk, not a new standard. It does not settle whether 15-fraction concurrent chemoRT matches standard schedules for late toxicity.
- Late toxicity of 15-fraction concurrent chemoRT vs standard schedules recruiting Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC Phase 3n=311 · primary completion 2029-06 · phase 3 RCT hypofx vs conventional CCRT, safety endpoint
- Outcomes of single-fraction SABR adopted during the pandemic n=190 · primary completion 2028-11 · prospective 1-fx lung SBRT cohort, outcomes + QoL
- Validity of assumed α/β values for hypofractionated lung RT
📚 Sources · 📄 1 paper
The longer read
This is a guidance document, and it should be read as one. Its job was to give lung radiotherapy departments a defensible set of shorter schedules at a moment when every hospital visit carried infection risk and staffing was unpredictable. What it offers a radiation oncologist now is less a set of rules than a map of how far fractionation can be compressed before the evidence thins out.
The strongest ground is stereotactic treatment of small peripheral tumours. Single-fraction delivery of 30Gy to 34Gy has the most direct support, and the guidance pairs it with a sharp chest wall caveat: in a cited series, chest wall toxicity ran 30.6% for lesions abutting the chest wall against 8.2% for tumours close to it, with overall grade ≥3 chest wall toxicity of 1.4%. That gradient is the practical message. Single-fraction SABR is a reasonable compression for the right geometry and a poor one when the target sits on the chest wall. The 50Gy in 5 fraction schedule used in Glasgow is anchored to RTOG 0813 constraints, which gives it a recognisable safety frame.
The radical conventional-to-hypofractionated step is weaker ground. The case for moving from 55Gy/20 to 15 fractions is radiobiological: 52Gy/15 is quoted as isoeffective for tumour control at an α/β of 10, and 50Gy/15 as isotoxic for late effects at an α/β of 3. That is internally consistent but entirely dependent on the assumed α/β values and on the linear-quadratic model holding across the dose range. A reader should treat these as planning hypotheses, not demonstrated equivalence.
Chemoradiation is where caution matters most. The cited cohort reporting 25% ≥grade 3 oesophagitis and 10% ≥grade 3 pneumonitis with concurrent chemotherapy is a reminder that compressing fractionation with a systemic backbone concentrates acute toxicity. The 40Gy in 15 fraction option is described as used concurrently and sequentially, but the supporting data are retrospective and heterogeneous.
Methodologically, the document is honest about its base: most hypofractionation data are retrospective single-institution series. The toxicity figures across sections come from different cohorts, regimens and selection, so they cannot be lined up against each other. For larger tumours the guidance holds the line on organ-at-risk constraints, noting one series with 30% grade ≥3 toxicity, pneumonitis most common.
What it changes is the menu, not the default. Outside a resource crisis, it supports single-fraction SABR for well-placed small tumours and gives a modelled rationale for 15-fraction radical schedules; it does not establish that those schedules match standard fractionation for late toxicity in chemoradiation.